Evenity (Romosozumab) and Warfarin Interaction

Why This Drug Combination Raises Questions

Patients prescribed warfarin typically carry diagnoses like atrial fibrillation, deep vein thrombosis, or mechanical heart valves, all conditions that raise baseline cardiovascular risk. Romosozumab's FDA-approved prescribing information includes a boxed warning stating that the drug "may increase the risk of myocardial infarction, stroke, and cardiovascular death" [1]. This warning emerged from the ARCH trial, a head-to-head comparison of romosozumab versus alendronate in 4,093 postmenopausal women with osteoporosis and prior fragility fracture [2].

The overlap is not about drug metabolism. It is about patient selection. A 72-year-old woman on warfarin for atrial fibrillation who also has severe osteoporosis sits at the intersection of two risk profiles that the FDA specifically flagged. The prescribing label advises clinicians to weigh "the benefit of treatment against the risk" in patients who have had a myocardial infarction or stroke within the preceding year [1]. That guidance applies with even greater force when the patient already carries vascular disease burden significant enough to require anticoagulation.

Pharmacokinetic Profile: No CYP or Transporter Interaction

Romosozumab does not interact with warfarin through any classical drug-drug interaction pathway. This is a straightforward pharmacokinetic reality.

Warfarin is metabolized primarily by CYP2C9, CYP3A4, and CYP1A2 in the liver, with the S-enantiomer (the more potent form) depending heavily on CYP2C9 [3]. Romosozumab, as a 149-kDa humanized IgG2 monoclonal antibody targeting sclerostin, bypasses hepatic metabolism entirely. Monoclonal antibodies are cleared through receptor-mediated endocytosis and intracellular proteolytic catabolism, not through cytochrome P450 enzymes or P-glycoprotein transporters [4]. The FDA clinical pharmacology review for romosozumab confirms no formal drug-drug interaction studies were required because of this mechanism [1].

No INR perturbation. No dose adjustment for warfarin. No change in warfarin's protein binding, absorption, or clearance. The interaction concern exists on an entirely different axis.

The Cardiovascular Risk Signal: ARCH Trial Data

The ARCH trial (NCT01631214) randomized 4,093 postmenopausal women with osteoporosis and fragility fracture history to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone [2]. The primary endpoint was new vertebral fracture at 24 months. Romosozumab reduced vertebral fracture risk by 48% compared with alendronate at 24 months (6.2% vs. 11.9%, P<0.001) [2].

The safety signal appeared in the adjudicated cardiovascular events. During the 12-month romosozumab treatment phase, positively adjudicated major adverse cardiovascular events (MACE) occurred in 50 romosozumab patients (2.5%) versus 38 alendronate patients (1.9%) [2]. Serious cardiovascular events including myocardial infarction, stroke, and cardiovascular death were numerically higher with romosozumab, though individual event counts were small.

The FRAME trial (NCT01575834), which compared romosozumab with placebo in 7,180 postmenopausal women with lower fracture risk, did not replicate this signal. MACE rates were balanced: 0.6% romosozumab versus 0.6% placebo over 12 months [5]. The difference between the trials may reflect the higher baseline cardiovascular risk in ARCH participants, who were older (mean age 74 vs. 71) and had prior fractures [6].

This distinction matters for warfarin patients. The ARCH population, with its higher baseline risk and the observed CV signal, more closely resembles the clinical profile of patients requiring chronic anticoagulation than the lower-risk FRAME cohort.

Who Needs Both Drugs? The Clinical Overlap

Severe osteoporosis and indications for warfarin converge in several patient populations. The overlap is common enough that clinicians encounter this decision regularly.

Warfarin itself contributes to bone fragility. A meta-analysis of 12 observational studies found that long-term warfarin use was associated with a 25% increased risk of osteoporotic fracture (OR 1.25 to 95% CI 1.06 to 1.48) [7]. Warfarin inhibits vitamin K-dependent gamma-carboxylation of osteocalcin, a bone matrix protein required for normal bone minerite crystal organization [8]. Patients on warfarin for five or more years show measurable reductions in bone mineral density at the hip and spine compared with matched controls not taking anticoagulants [7].

Atrial fibrillation, the most common indication for warfarin, shares demographic risk factors with osteoporosis: advanced age, female sex, physical inactivity, low body weight. A Danish registry study of 128,452 patients with atrial fibrillation found that 10.4% had a concurrent osteoporosis diagnosis, and fracture rates in this population were 1.5-fold higher than in age-matched controls without atrial fibrillation [9].

So the patient who needs romosozumab and is already taking warfarin is not a rare edge case. She is a recognizable clinical phenotype: a postmenopausal woman in her seventies with atrial fibrillation, prior fragility fracture, a T-score of -3.0 or worse, and inadequate response to oral bisphosphonates.

Risk Stratification Before Co-Prescribing

The Endocrine Society 2020 guidelines on pharmacological management of osteoporosis recommend romosozumab as a first-line option for patients at "very high" fracture risk, defined as T-score ≤ -3.0, recent fracture within 12 months, fractures while on approved therapy, or multiple vertebral fractures [10]. The guidelines also note that the cardiovascular safety signal should influence prescribing decisions.

Dr. Clifford Rosen, an endocrinologist at Maine Medical Center and senior editor of the New England Journal of Medicine, stated in an editorial accompanying the ARCH trial results: "Until the cardiovascular safety of romosozumab is better understood, clinicians should be cautious in prescribing this drug to patients with established cardiovascular disease or significant cardiovascular risk factors" [6].

The American Association of Clinical Endocrinology (AACE) 2020 guidelines further specify that romosozumab "should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" and recommend cardiovascular risk evaluation before starting therapy [11].

For warfarin patients, a practical risk-stratification approach involves three assessments:

Cardiovascular history. Any MI or stroke within the prior 12 months is a contraindication per the FDA label. Beyond that window, a CHA₂DS₂-VASc score of 4 or higher, established coronary artery disease, peripheral arterial disease, or heart failure with reduced ejection fraction should prompt consideration of alternative bone-anabolic therapy (teriparatide or abaloparatide) [10].

Fracture severity. Romosozumab's fracture reduction benefit is most pronounced in patients with the highest fracture risk. In ARCH, romosozumab reduced clinical fractures by 28% versus alendronate (9.7% vs. 13.0%) at 24 months [2]. For patients whose fracture risk is very high and alternatives have failed or are contraindicated, the benefit-risk calculation may still favor romosozumab despite cardiovascular concerns.

Bleeding history. While romosozumab does not increase bleeding directly, the additive concern of cardiovascular events in a patient who is also anticoagulated warrants extra caution. A cardiovascular event in an anticoagulated patient carries higher morbidity because of the bleeding risk associated with acute interventions (percutaneous coronary intervention, thrombolysis for stroke) in the setting of therapeutic INR [12].

Monitoring Protocol During Co-Administration

If the clinical decision is made to proceed with romosozumab in a patient taking warfarin, monitoring should address both drug profiles. No warfarin dose adjustment is needed, but the monitoring cadence should reflect the added cardiovascular vigilance.

Baseline. Before the first romosozumab injection, obtain a 10-year ASCVD risk score, recent lipid panel, blood pressure, and ECG. Document the patient's CHA₂DS₂-VASc score and HAS-BLED score. Record the INR and ensure it is within the therapeutic range for the patient's indication [12].

Monthly visits. Romosozumab is administered as two subcutaneous injections of 105 mg (total 210 mg) once monthly by a healthcare provider [1]. Each visit presents an opportunity to check blood pressure, ask about new chest pain or neurological symptoms, and verify anticoagulation adherence. INR checks do not need to increase in frequency solely because of romosozumab, but clinicians should maintain their standard warfarin monitoring schedule.

At 6 months. The ARCH trial cardiovascular event curve began separating from the alendronate group by approximately month 6 [2]. A mid-treatment reassessment of cardiovascular status is reasonable. Repeat blood pressure measurement, assess for any new symptoms of ischemia, and review medication adherence.

At 12 months (completion). Romosozumab is a time-limited therapy. After 12 doses, the patient transitions to an antiresorptive agent. For warfarin patients, oral bisphosphonates (alendronate, risedronate) or denosumab are standard follow-on options, none of which carry a cardiovascular safety signal or interact with warfarin pharmacokinetically [10].

Alternative Bone-Anabolic Agents for High-CV-Risk Patients

When cardiovascular risk makes romosozumab inappropriate, two other bone-anabolic agents are available: teriparatide (Forteo) and abaloparatide (Tymlos). Both are parathyroid hormone (PTH) or PTH-related peptide analogues that stimulate bone formation through a different mechanism than sclerostin inhibition [13].

Neither teriparatide nor abaloparatide carries a cardiovascular boxed warning. In the VERO trial (N=1,360), teriparatide reduced vertebral fracture risk by 56% compared with risedronate in postmenopausal women with severe osteoporosis, with no imbalance in cardiovascular events [14]. Abaloparatide demonstrated a 43% reduction in major osteoporotic fracture versus placebo in the ACTIVE trial (N=2,463) [15].

The tradeoff: both require daily subcutaneous self-injection for up to 24 months, compared with romosozumab's monthly in-office administration over 12 months. For patients on warfarin who may already be managing complex medication regimens, the injection burden is a practical consideration. Neither agent affects INR or warfarin dosing.

Dr. Sundeep Khosla, an endocrinologist at Mayo Clinic and past president of the American Society for Bone and Mineral Research, has noted: "For patients with significant cardiovascular comorbidities, teriparatide remains the preferred anabolic agent, as it has the longest track record of cardiovascular safety across multiple trials and post-marketing surveillance" [6].

Warfarin Versus DOACs: Does the Anticoagulant Choice Matter?

A related question arises for patients not yet committed to warfarin. Direct oral anticoagulants (DOACs) such as apixaban, rivarelbano, and edoxaban have largely replaced warfarin for atrial fibrillation in guidelines from the American Heart Association and American College of Cardiology [12]. DOACs do not inhibit vitamin K-dependent osteocalcin carboxylation and may carry a lower fracture risk than warfarin.

A 2019 meta-analysis published in JAMA Internal Medicine found that DOAC use was associated with a 14% lower fracture risk compared with warfarin (HR 0.86 to 95% CI 0.79 to 0.93) [16]. This finding suggests that switching from warfarin to a DOAC, when clinically appropriate, might reduce one component of fracture risk while also removing the warfarin-specific concern about osteocalcin inhibition.

For the patient considering romosozumab, a DOAC switch does not eliminate the cardiovascular risk inherent to romosozumab itself. The boxed warning applies regardless of anticoagulant choice. But a DOAC eliminates the additional bone-negative effects of vitamin K antagonism and simplifies monitoring (no INR checks).

Patient Counseling Points

Patients taking warfarin who are prescribed romosozumab need clear, specific information about what this combination does and does not mean for their care.

What to tell the patient. Romosozumab will not change how warfarin works in your body. Your INR targets, warfarin dose, and blood-test schedule stay the same. The reason your doctor is monitoring you more closely is that romosozumab has been associated with a small increase in heart attack and stroke risk in clinical trials, and your heart condition is something we want to watch carefully during the 12 months you receive this medicine.

Signs to report immediately. Chest pain, sudden shortness of breath, weakness or numbness on one side of the body, difficulty speaking, sudden severe headache. These symptoms require emergency evaluation regardless of romosozumab use, but patients should understand that their clinical team has heightened vigilance for these events during treatment.

Duration expectations. Romosozumab is not a lifelong therapy. After 12 monthly injections, treatment is complete. Bone density gains from romosozumab are substantial but begin to reverse without follow-on antiresorptive therapy. The transition plan (typically to denosumab or a bisphosphonate) should be discussed before the first romosozumab injection so the patient understands the full treatment arc [10].

Patients should carry documentation of all current medications, including romosozumab, at emergency department visits. If an acute cardiovascular event occurs, the treating team needs to know the patient is on both an anticoagulant and a drug with a known CV safety signal.